***Background.*** Multidrug-resistant Gram-negative bacteria have become established in hospitals in New York City. Novel antibiotics are sorely needed to treat infections due to multidrug-resistant strains. Eravacycline is a novel fluorocycline, and is not affected by common mechanisms leading to tetracycline resistance. In this study we examine the activity of eravacycline against Gram-negative pathogens from New York City, a region plagued by MDR strains.

***Methods.*** From November 2013 through January 2014, single patient bacterial isolates were gathered from 11 hospitals in Brooklyn and Queens, NY. Isolates underwent susceptibility testing by dilution techniques according to CLSI methodology. Cephalosporin-resistant isolates were also screened by PCR for the presence of *bla*~KPC~.

***Results.*** Among 2866 isolates of *E. coli*, 87% were susceptible to cephalosporins and 99.8% to carbapenems; two possessed *bla*~KPC~. For 944 *Klebsiella pneumoniae*, 67% were susceptible to cephalosporins and 86% to carbapenems; 13% possessed *bla*~KPC~. For 216 *Enterobacter* spp., 75% were susceptible to cephalosporins and 95% to carbapenems; 3% possessed *bla*~KPC~. For 158 *Acinetobacter baumannii*, 34% were susceptible to cephalosporins and 31% to carbapenems. The susceptibility results for tetracycline and eravacycline are listed in the table.

Among 125 isolates of *K. pneumoniae* with *bla*~KPC~, the MIC~50~ and MIC~90~ values for eravacycline were 0.5 and 1.0 µg/ml, respectively. For 96 isolates of *A. baumannii* resistant to carbapenems, the MIC~50~ and MIC~90~values were 0.5 and 2 µg/ml, respectively.

                                MIC~50~   MIC~90~   Range          Percent susceptible
  ----------------------------- --------- --------- -------------- ---------------------
  *E. coli* (n=2866)                                               
  Tetracycline                  4         \>16      ≤0.25 - \>16   59%
  Eravacycline                  0.12      0.5       ≤0.015 - 4     
  *K. pneumoniae* (n=944)                                          
  Tetracycline                  4         \>16      1 - \>16       68%
  Eravacycline                  0.25      1         ≤0.06 - 8      
  *Enterobacter* spp. (n=216)                                      
  Tetracycline                  2         16        ≤0.25 - \>16   78%
  Eravacycline                  0.5       1         ≤0.12 - 2      
  *A. baumannii* (n=158)                                           
  Tetracycline                  \>16      \>16      2 - \>16%      10%
  Tigecycline                   2         \>2       ≤0.06 -\>2     66%
  Eravacycline                  0.5       1         ≤0.015 - 4     

***Conclusion.*** Eravacycline is a novel antibacterial agent with excellent in vitro activity against *E. coli*, *K. pneumoniae*, *Enterobacter* spp. and *A. baumannii*, including multidrug-resistant isolates.
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